B Cell News and Research

RSS

Study reframes Hodgkin lymphoma as a cancer of failed cell development

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an "identity crisis."

24 Apr 2026

Researchers identify molecular link between autoimmune disease and lymphoma risk

Patients with autoimmune diseases such as lupus and rheumatoid arthritis have an increased risk of developing lymphoma, a form of blood cancer that affects the lymphatic system.

13 Apr 2026

FDA clears investigational new drug application to test sCAR-T therapy for autoimmune conditions

Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions.

10 Apr 2026

Gut-derived metabolites regulate immune cells in complex ways

Published on March 23, 2026, in Volume 2, article number 18 of the journal Immunity & Inflammation, the review begins by systematically outlining the sources and synthetic pathways of immune-relevant microbial metabolites, including bile acids, short-chain fatty acids, amino acid derivatives, vitamins, trimethylamine/trimethylamine N-oxide, and odd-chain fatty acids.

31 Mar 2026

Study reveals how inflammation disrupts lymph node structure in lymphoma

In aggressive lymphomas, inflammatory messengers reprogram the "conductors" of the immune system, causing lymph nodes structure to collapse.

26 Mar 2026

Early blood test could guide personalized lymphoma treatment decisions

Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of treatment: an antibody designed to wipe out cancerous B cells plus a combination of four chemotherapy drugs.

25 Mar 2026

Innovative platform detects diseases using a single drop of blood

An innovative platform developed by PKU researchers called "cf-EpiTracing" has proved capable of detecting and tracing diseases from as little as 50 μl of human plasma, or roughly a drop of blood.

16 Mar 2026

New insights highlight multifaceted roles of CD4+ T cells in tumor immunity

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell killing.

13 Mar 2026

Prior flu exposure may weaken the immune response to other strains

Prior exposure to one strain of influenza virus may weaken children's ability to mount an effective antibody response against their subsequent exposure to a different flu strain, according to a study led by Weill Cornell Medicine investigators.

11 Mar 2026

DNA origami vaccine platform shows promise against multiple infectious viruses

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December 2020 and mathematical models suggest that mRNA vaccines prevented at least 14.4 million deaths from COVID-19 in the first year alone.

11 Mar 2026

Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation

Intranasal boosting after prior intramuscular COVID vaccination induced strong mucosal IgA responses in a small human cohort. These antibodies showed markedly enhanced neutralising activity against Omicron variants and evidence of immune memory reprogramming toward mucosal protection.

15 Feb 2026

Gut microbial butyrate enhances mucosal vaccine antibody responses

A research team from POSTECH and ImmunoBiome in Korea, led by Professor Sin-Hyeog Im, has uncovered a new mechanism showing how butyrate-a short-chain fatty acid produced by gut commensal bacteria-enhances T follicular helper (Tfh) cell activity to promote antibody production and strengthen mucosal vaccine efficacy.

4 Feb 2026

Antibody-producing plasma cells shape effectiveness of PD-1 immunotherapy

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not.

27 Jan 2026

Suppressing brain immune cells enhances memory recall in young mice

Babies of every species from mouse to human rapidly forget things that happen to them-an effect called infantile amnesia.

20 Jan 2026

Far-red light suppresses biofilm formation and virulence in pathogenic bacteria

Light is a universal stimulus that influences all living things. Cycles of light and dark help set the biological clocks for organisms ranging from single-celled bacteria to human beings.

20 Jan 2026

Customizable protein platforms offer new hope for cancer treatment

Precise methods for shredding or repairing and replacing specific cancer-causing proteins in a malignant cell, developed at the University of Massachusetts Amherst, could have applications beyond cancer to a wide range of immunological diseases, members of the interdisciplinary research team say.

20 Jan 2026

Blocking microglia can prevent infantile amnesia

Scientists have found that blocking microglia (specialist immune cells in the brain) prevents infant forgetting ("infantile amnesia") and improves memory in mice, suggesting that microglia may actively manage memory formation and dictate what, and when, we forget.

20 Jan 2026

Atypical mutation offers clues to personalized pancreatic cancer treatment

A new study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants.

20 Jan 2026

Researchers discover a biochemical route that plays role in Parkinson's disease

About 1 million Americans suffer from Parkinson's disease, with around 90,000 new cases diagnosed each year, according to the Parkinson's Foundation.

20 Jan 2026

ELRIG announces Drs Stephen Ward and Annarita Miccio as keynote speakers for Cell and Gene Therapy 2026

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speakers for Cell and Gene Therapy 2026. Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute) will lead the inaugural two-day event taking place at Hinxton Hall in Cambridge, UK from 9-10 March.

20 Jan 2026